Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may predict cure and detect resistance in B-Cell cancers

NCT ID NCT03280394

Diagnosis Sponsor: Oncology Institute of Southern Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study is testing whether a blood test that looks for tumor DNA in the bloodstream (called a liquid biopsy) can help doctors manage patients with mature B-cell tumors. The goal is to see if the test can accurately predict who is cured after treatment and identify early signs of drug resistance. Researchers will follow about 444 adults with various B-cell cancers, including Hodgkin lymphoma and diffuse large B-cell lymphoma, to compare the blood test results with standard outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Liquid Biopsy (blood test for cell-free DNA)
What this could lead to
If successful, this blood test could help doctors predict which patients are cured after treatment and spot early signs of drug resistance, guiding more personalized care.
What could go wrong
This is an observational study, not a treatment trial. The test may not prove accurate enough for routine use, and results may not apply to all types of B-cell tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 444 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2017

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Male or female adults 18 years or older with a documented diagnosis of mature B-cell tumor according to WHO 2008 criteria

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female adults 18 years or older * Documented diagnosis of mature B-cell tumor according to WHO 2008 criteria * Willing and able to comply with scheduled study procedures * Evidence of a signed informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mature B-cell neoplasm are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma mantle cell lymphoma neoplasm of mature B-cells

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mature B-cell neoplasm

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institute of Oncology Research

    RECRUITING

    Bellinzona, Canton Ticino, 6500, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.